

1 **Biological diagnosis and characterization of occult hepatitis B virus infection in Burkina**
2 **Faso.**

3 Boubacar Doumbia¹, Birama Diarra², Bourahima Kone³, Florencia Djigma², Bocar Baya³,
4 Jacque Simpore²

5 ¹ National Institute of Public Health, Bamako, Mali

6 ² Biological and Molecular Genetics Laboratory (LABIOGENE) of Ouaga University Pr.
7 Joseph Ki-Zerbo, Burkina Faso

8 ³ University Center of Clinical Research, Bamako, Mali

9 **Corresponding Authors:** Dr. Boubacar Doumbia, National Institute of Public Health (INSP),
10 Biological Medical Research Laboratory Department (BRLD); Medical Biological Laboratory
11 Service, Email: doumbiab44@gmail.com, Phone: 00223 76087760

12 **Email address list:** Boubacar Doumbia (doumbiab44@gmail.com), Birama Diarra
13 (diarra.birama679@gmail.com), Florencia Djigma (master.biogema@gmail.com), Bourahima
14 Koné (bilema2006@gmail.com), Bocar Baya (bbaya@icermali.org), Jacques Simpore
15 (jacques.simpore@labiogene.org)

16 **Keywords:** OBI, Multiplex PCR, Genotyping, Burkina Faso.

17 **Conflict of interest:** the authors declare that they have no conflict of interest.

18

19

20

21

22

23

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract**

27 **Introduction/objective:** The occult infection by the hepatitis B virus (OBI) characterized by
28 the undetectable (HBs Ag) negative antigen in the serum and the presence of viral DNA,
29 constitutes a major public health problem and a major challenge for clinical forms of hepatitis
30 worldwide. The persistence of OBI very often leads to hepatocellular carcinoma (HCC) and
31 immunodeficiency. The aim of this study was to estimate the prevalence of OBI and to
32 characterize the incriminated genotypes of the virus.

33 **Material and method:** The plasmas of 252 HBsAg-negative volunteers were used for
34 highlighting the viral DNA by PCR classic. PCR Multiplex using specific primers of 6
35 genotypes (A to F) was used for characterization.

36 **Results:** A prevalence of 11.9% (30/252) of OBI was obtained with 7.5% in women and 4.4%
37 for men. Genotypes E (60.0%) and A3 (23.3%) were present and genotypes B, C, D, and F were
38 absent. A mixed infection with E/A3 genotypes (16.7%) was observed. AC Anti-HBc was
39 present in 80% of cases OBI.

40 **Discussion/Conclusion:** The prevalence of 11.9% of OBI could be related to the level of
41 endemicity of the study area, Burkina Faso being a country with a prevalence of more than 14%
42 of HBV infection. These infections are dominated by the A3 and E genotypes, confirming their
43 importance in chronic HBV infections. The absence of genotypes B and C in cases of OBI
44 constitutes a positive predictive value since their presence is linked to a more rapid evolution
45 of the infection towards HCC.

46 **Keywords:** OBI, Multiplex PCR, Genotyping, Burkina Faso

47

48

49

50

52 1. Introduction

53 Hepatitis B virus (HBV) infection remains a major public health problem in the world.
54 According to the World Health Organization, approximately 2 billion people are infected with
55 the hepatitis B virus (HBV). Carriers of chronic hepatitis B are estimated at about 350 million,
56 of whom more than 700,000 die each year from cirrhosis and/or hepatocellular carcinoma
57 (HCC) [1]. Burkina Faso (BF) is a highly endemic country with HBV prevalence varying
58 between 8% and 14.5% in the general population [2, 3]. Prevalences of 14.3%; 17% and 12.9%
59 were reported respectively among blood donors from Nouna, from Ouagadougou and the
60 national blood transfusion center of Burkina Faso [4, 5]. Blood transfusion constitutes of a
61 major risk factor for transmission of the OBI virus following blood screening of donors without
62 the use of nucleic amplification tests [6, 7]. The use of nucleic acid amplification tests to screen
63 blood donors for HCV, HIV, HBV, and OBI can prevent the occurrence of infections due to
64 these viruses [8]. The implementation of these nucleic amplification tests is not yet an
65 achievement for developing countries. The prevalence of OBI among blood donors varies from
66 country to country [9]. In Burkina Faso, this prevalence was around 32.8% among blood donors
67 [10]. The detection of HBV surface antigen (HBsAg) in serum remains the basic element in the
68 diagnosis of chronic infection and for HBV screening in developing countries [11]. And the
69 majority of HBsAg positive individuals are also positive for HBV DNA in serum. Occult HBV
70 infection (OBI) is characterized by the presence of viral DNA in individuals with undetectable
71 HBsAg, with the presence or absence of anti-HBc antibody [12]. Chronic carriers of hepatitis
72 C virus (HCV) and human immunodeficiency virus (HIV) are associated with a high prevalence
73 of OBI [13, 14]. OBI/HCV coinfection accelerates the progression of hepatitis to cirrhosis and
74 increases the risk of progression to hepatocellular carcinoma (HCC) [15]. This coinfection also
75 decreases the response to hepatitis treatment with the alpha interferon [16]. The molecular
76 mechanisms underlying the occurrence of OBI play a direct role in the development of

77 hepatocellular carcinoma (HCC) [17, 18]. The HBV genome is genetically variable.
78 Phylogenetic studies have classified HBV into 10 genotypes (A-J) [19, 20]. These genotypes
79 and their variants (sub-genotypes) have a distinct geographic distribution and have been
80 associated with the development of cirrhosis and liver cancer (HCC) [21]. This genetic
81 variability of HBV plays an important role in the occurrence of OBI [22, 23]. In Burkina Faso,
82 we have few data on the prevalence of occult hepatitis B virus infection in the general
83 population. The aim of this study was to estimate the prevalence of occult HBV infection and
84 to characterize the genotypes of the virus implicated in volunteers in the population of
85 Ouagadougou.

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102 2. Materials and Methods

103 **Study framework:** The study took place at the laboratory of Biological and Molecular Genetic
104 (LAOBIGENE) of the University Ouaga I Pr Joseph Ki-Zerbo in Burkina Faso.

105 **Type, populations and study period:** This is a prospective study, which was carried out
106 between June 2018 and December 2019. This is a population of two hundred and fifty-two
107 (252) volunteers residing in Ouagadougou, without distinction of age, professions or social
108 categories who have given their free and informed consent. For children, consents have been
109 obtained from parents or guardians. The recruitment of volunteers took place in different
110 sentinel sites in Ouagadougou after an awareness campaign lasting several days for screening
111 for hepatitis B. After obtaining the free and informed consent of the participants, screening for
112 HBV was carried out in using a rapid diagnostic test (RDT). The collection of blood samples
113 concerned the HBs antigen negative participants.

114 **Sampling:** A blood sample was taken from all participants who were HBs antigen negative. A
115 volume of 4 ml of venous blood was drawn into the EDTA tubes. After sedimentation for two
116 hours (2 hours), the plasmas were decanted from the pellets to prepare different aliquots. These
117 plasma aliquots were stored at -20°C in freezers before proceeding to HBV detection.

118 Hepatitis B virus (HBV) detection

119 ➤ DNA extraction:

120 It was performed using the Genomic Column DNA Express kit (Sacace Biotechnologies,
121 Como, Italy) according to the manufacturer's protocol. The protocol uses a column extraction
122 method based on a principle of retention of nucleic acid molecules on a silicate membrane
123 contained in a column. The cells are first lysed by a solution containing chaotropic ions in the
124 presence of proteinase K. After a washing step which rids the sample of contaminants, the
125 nucleic acid is recovered by elution in a slightly alkaline solution. The pure product (the nucleic
126 acid) can therefore be directly amplified.

127 ➤ **Classical PCR**

128 It was carried out using the procedure of the manufacturer AmpliTaq Gold 360 Master Mix, by
129 amplification of a very conserved region (Pres-S) of 1104 bp of the HBV genome.

130 The primer pair used (Table I) was designed from a highly conserved region of the HBV S
131 surface envelope. The PCR was carried out with the GeneAmp PCR System 9700 ® device
132 (Applied Biosystems, USA) in a reaction volume of 25 µl which contained 12.5 µl of Master
133 mix Ampli Gold Taq Man (Applied Biosystems, USA), 1 µl of forward and reverse primers
134 and 5.5 µl of sterile water and 5 µl of DNA. The PCR products were subjected to electrophoresis
135 on a 2% agarose gel prepared with ethidium bromide (10 mg/ml), and visualized under UV
136 light at 312 nm.

137 **Electrophoresis and Revelation under Ultra Violet (UV) light**

138 The transparent support containing the gel was placed in the electrophoresis tank containing
139 migration buffer. The samples were placed on the gel while ensuring that the migration buffer
140 previously poured into the tank covers the gel by a few millimeters. To do this, 5 µl of loading
141 blue were mixed with 5 µl of amplified cDNA per sample and placed in appropriate wells on
142 the gel. Three (3) µl of the molecular weight marker (Ladder) were deposited in the first well.
143 Electrophoretic migration at 120 V for 45 minutes. The gel was revealed under UV at 312 nm
144 then photographed by the “GENE FLASH®” device. Results interpretation: The PCR was
145 declared positive if the sample shows a band corresponding to the size of the expected DNA
146 fragment (**Table I**). It was negative in the absence of band.

147 ➤ **Characterization of genotypes by multiplex PCR**

148 The multiplex PCR was carried out using the method described by Chen et al, with the
149 following modifications: Two PCR-Multiplexes under the same conditions with two Mixes.
150 Mix 1 will characterize genotypes A to C and Mix 2 genotypes D to F. The two PCR-
151 Multiplexes were carried out in a total volume of 25 µl containing 12.5 µl of Master mix Ampli

152 Gold Taq Man® (Applied Biosystems, USA), 1 µl of sense and antisense primers of the 3
153 genotypes (**Table II**), 1.5 µl of sterile water and 5 µl of DNA. Interpretation of results, the PCR
154 was considered positive if the sample shows a band corresponding to the size of the expected
155 DNA fragment. It was negative in the absence of the band. The sizes of the fragments and their
156 corresponding genotypes are shown in Table II.

157 ➤ **Rapid detection tests for HBV markers**

158 **Principles**

159 **HBs Ag and HBe Ag antigens:** Immuno-chromatographic method using the ELISA technics
160 (Enzyme Link Immuno-Sorbent Assay) in sandwich. The anti-HBsAg and anti-HBeAg
161 antibodies fixed on the test membrane react with the HBsAg and HBeAg antigens of the serum
162 to be tested and the Ag-AC couples migrate by capillary action to encounter other anti-HBsAg
163 and anti-Ag antibodies at the second level of the test. HBe and give a colored reaction indicating
164 the positivity of the test.

165 **Anti-HBs antibodies:** Immuno-chromatographic method, it consists of fixing the anti-HBs
166 antibodies of serum by HBsAg previously fixed to the membrane of the test, then fixing by a
167 second sandwiched HBsAg at the second level of the test after migration by capillarity.

168 **Anti HBe and anti HBC antibodies:** Immuno-chromatographic method using the competitive
169 ELISA technique. The anti-HBe and anti-HBc antibodies compete with other anti-HBe and
170 anti-HBc antibodies fixed on the membrane, for the HBeAg and HBcAg previously fixed on
171 the membrane. The positive result is characterized by the absence of a line because there is
172 competition between the antibodies.

173 **Data collection tools:** The data was entered on Excel software and analyzed on SPSS version
174 25 software. The significance level was set at $p < 0.05$.

175 **Ethical consideration:** This study was carried out taking into account the free and informed
176 consent of the participants. Respect for confidentiality and anonymity in relation to the provided
177 information was essential. The study caused the approval of the institutional ethic committee
178 of CERBA/LAOBIGENE and the national ethics committee of the Ministry of Health of
179 Burkina Faso.

180 **3. Results**

181 The present study focused on 252 volunteers screened for viral hepatitis B virus (HBV), all
182 negative for HBV surface antigen (HBsAg). Of the 252 individuals with undetectable HBsAg,
183 viral DNA was present at 30 or 11.9%. The seroprevalence of occult HBV infection was 13.77%
184 in women against 9.65% in men. It was respectively 9.30%, 16.39%, 3.39% and 14.29%, in the
185 age groups of less than 20 years, 20-34 years, 35-50 years and more than 50 years. It was 10%
186 based on rural origin against 11.98% urban origin. On the marital level, the prevalence was
187 12.50% and 11.43% respectively among singles and married people (**Table III**). The presence
188 of genotypes E and A3 was recorded with respectively 60.0% (18/30) and 23.3% (7/30) (**Figure**
189 **1**) (**Table IV**). Genotypes B, C, D, and F were absent. A mixed infection with E/A3 genotypes
190 (5/30 or 16.7%) was identified in some samples. The prevalences of serological markers of
191 occult HBV infection were respectively 80%, 13.3%, 10.0% and 0.0% for Ac HBc, Ac HBe,
192 Ac HBs and Ag HBe respectively. The HBc Ac seropositive IOB was 80.0% against 20% of
193 the seronegative IOB. No coinfection with HCV was found in the cases of IOB (**Table V**).

194 **4. Discussion**

195 Occult hepatitis B defined by the presence of viral DNA in the serum and/or in the hepatocytes
196 and the absence of detectable HBsAg, has been described since the 1970s. But during the last
197 decades that it has grown the size because of the reinforcement of the measures of transfusional
198 security and the organ transplantation development mostly in developed countries. Data on OBI

199 in developing countries are almost non-existent. In the literature the prevalence of OBI varies
200 according to the methods of detection and areas endemicity level. [9, 24]. Burkina Faso is a
201 country with a high endemicity for hepatitis viral B with a prevalence of more than 14% [2].

202 Among the 252 individuals who make up our study population, 138 (54.8%) were female and
203 114 (45.2%) males. The sex ratio was 0.97 in the favor of women as was the case in the study
204 conducted by Oluyinka and al, in Nigeria on OBI in blood donors, where the sex ratio was 0.62
205 [24]. However, in 2014 in Burkina Faso, Somda, found a sex ratio of 4 in the favor of men in
206 their study [10]. The majority participation of women in our study can be explained by a much
207 greater availability on their part in voluntary screening. The 20-34 age group was the largest in
208 terms of the number of participants in our study, as was the case in the study conducted by
209 Oluyinka and al. However, the 30-60 age group was the most important in the studies conducted
210 by Kalantari and al, and Baghbanian and al, on the prevalence of OBI in hemodialysis patients
211 and cancer patients in Iran [25, 26].

212 The distribution of OBI generally varies from region to region and according to risk group [9].
213 In the present study, we recorded a global prevalence of 11.9% (30/252) of OBI which may be
214 related to the level of endemicity of the study of area to HBV infection. The prevalence of
215 occult HBV infection varies according to the study of area and the study population, thus a
216 prevalence of 17% (i.e. 72/429) was registered by Oluyinka and al., among Nigerian blood
217 donors; 32.8% (25/76) was obtained by Somda and al., among Burkinabe blood donors; 5.5%
218 (55/1000) by Shuaibu and al., among blood donors Malaysian; 0.13% (5/2972) by Hong Lin
219 and al., among Chinese blood donors; 4.8% and 4.3% by Baghbanian and al., among Iran in
220 blood and liver cancer patients respectively [9]. According to Makvandi and al., this variability
221 in OBI prevalence depends on the sensitivity of the molecular techniques used (nested PCR,
222 real-time PCR, or classical PCR) for the detection of viral DNA in serum and/or in hepatocytes,
223 the size of the sample used and the geographic distribution of the study site. Thus, the

224 prevalence of OBI varies from 1% (Canada) to 87% (Mexico) in different regions of the world
225 [27]. However, these prevalences should be interpreted with great caution. Indeed, according
226 to Samal and al., several factors can potentially influence the OBI estimation rate: risk groups
227 (chronic HCV infection, HIV infection, cirrhosis, injection drug users, hemodialysis patients,
228 and hepatocellular carcinoma), sample size, assays used for detection of mutant HBsAg and
229 HBV genome amplification targets, high and low endemicity regions [11]. However, even in
230 areas of low HBV endemicity such as Canada, cases of OBI have been reported [27]. The
231 seroprevalence of OBI varied in the different groups that constituted the study population. Thus,
232 this prevalence was 13.77% among women against 9.65% among men. According to age it was
233 9.30% among those under 20 and 3.39% between 35-50 years old. However, it had reached
234 16.39% among subjects aged 20 to 34 and 14.29 % in the over 50s. This variation of OBI in
235 specific groups has also been recorded by other authors. Thus, Baghbanian and al., registered a
236 prevalence of 4.3% in solid cancer patients and 4.8% in blood cancer patients [25]. There was
237 little difference between the prevalence in rural areas 10% and that in urban areas 11.98% this
238 similarity can be explained by the fact that it was the same study area. Characterization of
239 genotypes currently the genotypes found in cases of OBI in different regions of the world are
240 exclusively A, C, G, E and D [9]. In the present study we registered two genotypes E and A3.
241 These A3 and E genotypes were prevalent with respectively 23.3% and 60%, similar results
242 were found by Kurbanoy and al., in 2005 in Cameroon where genotypes A and E were in the
243 majority with 43.5% each, i.e., a total by 87% [28]. We registered a majority rate of genotype
244 E which corroborates the results found by Oluyinka and al. in 2015 Nigeria where all 72 cases
245 of OBI were of genotype E, and Yousif and al., in 2014 in Sudan with 21.6% of genotype E.
246 Furthermore in 2004, Mulders and al. in a multicenter study concerning the countries of West
247 Africa, had already proved the existence of genotype A and E of HBV in Burkina Faso [29].
248 Our study confirms the presence of the E genotype in the context of occult HBV infection with

249 a high prevalence of the E genotype. The E genotype of the HBV has a low genetic diversity
250 according to Mulders and al., and there is no difference between the genotype E of HBV
251 infection and that of occult HBV infection [24]. The A3 sub genotype registered in the present
252 study is a genotype that is usually present in Central Africa (Gabon, Cameroon, D.R Congo and
253 Central Africa) [30]; it has already been described in 2004 in Burkina Faso [29]. The persistence
254 of this genotype could be explained by the migration flow of populations between the different
255 areas of West and Central Africa. However, OBI genotypes A have been found in other parts
256 of the world [9], thus Escobedo and al., at 2014 in Mexico registered a case among 24 children
257 suffering from hepatitis, Youssif and al., at 2014 in Sudan registered a rate of 18.9%. We did
258 not register cases of occult B infection with genotypes B, C, D, and F in the present study.
259 While Hong Lin and al., in 2016 registered only genotypes B, C, and D in Chinese blood donors
260 with OBI [31]. The absence of these genotypes in our context, could be explained not only by
261 the geographic distribution of HBV infection, but also by the fact that we have not specifically
262 targeted groups at high risk of OBI: chronic hepatitis patients, HCC patients, HCV/HIV co-
263 infected, hemodialysis patients and immunocompromised patients. Indeed, a high prevalence
264 of genotypes B (24% or 6/25) and D (32% or 8/25) was observed in HCC patients with OBI in
265 Egypt [32] and these two genotypes were associated to a more rapid progression of the infection
266 to HCC. In Saudi Arabia, genotype D was the most prevalent in occult B cases in blood donors
267 (88.2% or 15/17). In our study we registered 5 cases (5/30 or 16.7%) of OBI recombination
268 between genotypes A3 and E. Similar results have been reported by other authors. Thus,
269 Makuwa and al, in 2006 in Gabon found 1 out of 13 cases of recombination between the A3
270 and E genotypes. Kurbanov and al., in 2005 also recorded cases of A3/E recombination
271 (43.5%) in Cameroon. However, in Sudan, the recombinations in cases of Occult B infection
272 mainly concerned the E/D genotypes with 13.5% [33].

273 We recorded 80% of cases of OBI seropositive against 20% of seronegativity to the antibody
274 anti-HBc. These data corroborate those found by Makvandi and al. in Iran during a state of
275 place on OBI (9). However, whether the OBI is seropositive or seronegative, the difference in
276 the clinical plan always remains encrypted [34]. The anti-HBs protective marker was present in
277 cases of OBI up to 10%, this phenomenon has already been described by Pernice and al. in
278 Marburg in Germany. In fact, they noticed that the appearance of detectable HBsAc in the
279 serum of patients, was correlated with the decrease or total absence of HBsAg [35]. Other
280 authors have been able to highlight the appearance of the HBsAg/anti-HBs immune complex
281 among patients of hepatocellular carcinoma with OBI [36].

282 **5. Conclusion**

283 At the end of this study, we were able to estimate a prevalence of 11.9% of cases of occult
284 infection of the hepatitis B virus (OBI) in a population of 252 volunteers. After genotyping of
285 cases of occult infections, genotypes B, C, D and F were absent while genotypes A3 and E were
286 present with 23.3% and 60.0% respectively. A mixed infection with both E/A3 genotypes
287 (16.7%) was also registered. OBI occupies a prominent place in certain groups of people such
288 as blood donors, chronic hepatitis from HCV, PV/HIV and cancer patients. It would be linked
289 to a much more rapid evolution of hepatitis towards hepatocellular carcinoma. The management
290 of these groups of people must systematically include the search for viral DNA and/or anti-HBc
291 antibodies in hepatocytes and/or in serum. However, the absence of circulating genotypes B
292 and D of OBI cases constitutes a positive predictive value since their presence has been
293 associated with a more rapid progression of the infection to hepatocellular carcinoma.

294

295

296

297

298 **6. Acknowledgment**

299 The research team thanks all the staff of Laboratory of Biology and Molecular Genetics
300 (LAOBIGENE) of the University Ouaga I Pr Joseph Ki-Zerbo Burkina Faso and the Medical
301 Biology Laboratory Department of the National Institute of Public Health/Bamako/Mali and all
302 candidates who participated in the study.

303 **7. Author contribution statement:** Doumbia B and Simpore J, designed the study, analyzed
304 and interpreted the results, and wrote the manuscript. Doumbia B, Diarra B, provided care for
305 study participants, developed the registry, and reviewed the manuscript. Djigma F collected and
306 checked the data, analyzed the data and reviewed the manuscript. Kone B and Baya B,
307 developed an analytical approach for data analysis and interpretation and revised the
308 manuscript. All authors have approved the final version of the manuscript before submission,
309 so they are fully responsible for its content.

310 **8. Declaration of conflict of interest:** The authors declare that they have no conflict of interest.

311 **9. References**

312 1. World Health Organization. Hepatitis B Fact Sheet N204. Hepatitis B. World Health
313 Organization. [Internet]. Available through: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/hepatitis-b)
314 [sheets/detail/hepatitis-b](https://www.who.int/news-room/fact-sheets/detail/hepatitis-b)

315 2. Tao I, Compaoré TR, Diarra B, Djigma F, Zohoncon TM, Assih M, and al. Seroepidemiology
316 of hepatitis B and C viruses in the general population of burkina faso. *Hepat Res Treat.*
317 2014;2014:781843.

- 318 3. Simpore J, Savadogo A, Ilboudo D, Nadambega MC, Esposito M, Yara J, and al. Toxoplasma
319 gondii, HCV, and HBV seroprevalence and co-infection among HIV-positive and -negative
320 pregnant women in Burkina Faso. *J Med Virol*. June 2006;78(6):730-3.
- 321 4. Collenberg E, Ouedraogo T, Ganamé J, Fickenscher H, Kynast-Wolf G, Becher H, and al.
322 Seroprevalence of six different viruses among pregnant women and blood donors in rural and
323 urban Burkina Faso: A comparative analysis. *J Med Virol*. May 2006;78(5):683-92.
- 324 5. Tao I, Bisseye C, Nagalo BM, Sanou M, Kiba A, Surat G, and al. Screening of Hepatitis G
325 and Epstein-Barr Viruses Among Voluntary non Remunerated Blood Donors (VNRBD) in
326 Burkina Faso, West Africa. *Mediterr J Hematol Infect Dis*. 2013;5(1):e2013053.
- 327 6. Candotti D, Allain J-P. Transfusion-transmitted hepatitis B virus infection. *J Hepatol*. Oct.
328 2009;51(4):798-809.
- 329 7. Allain J-P, Candotti D. Diagnostic algorithm for HBV safe transfusion. *Blood Transfus*
330 *Trasfus Sangue*. July 2009;7(3):174-82.
- 331 8. González R, Torres P, Castro E, Barbolla L, Candotti D, Koppelman M, and al. Efficacy of
332 hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV
333 infections among blood donors from Madrid, Spain. *Transfusion (Paris)*. January
334 2010;50(1):221-30.
- 335 9. Makvandi M. Update on occult hepatitis B virus infection. *World J Gastroenterol*. 21 Oct.
336 2016;22(39):8720-34.
- 337 10. Somda KS, Sermé AK, Coulibaly A, Cissé K, Sawadogo A, Sombié AR, and al. Hepatitis
338 B Surface Antigen Should Not Be the Only Sought Marker to Distinguish Blood Donors
339 towards Hepatitis B Virus Infection in High Prevalence Area. *Open J Gastroenterol*. 9 Nov.
340 2016;6(11):362-72.

- 341 11. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis
342 B virus infection. *Clin Microbiol Rev.* Jan. 2012;25(1):142-63.
- 343 12. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection
344 in chronic liver disease: full-length genome and analysis of mutant surface promoter.
345 *Gastroenterology.* Nov. 2004;127(5):1356-71.
- 346 13. Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus
347 infection: an update for the clinician. *World J Gastroenterol.* 28 March. 2011;17(12):1563-8.
- 348 14. Gupta S, Singh S. Occult hepatitis B virus infection in ART-naive HIV-infected patients
349 seen at a tertiary care centre in north India. *BMC Infect Dis.* 7 March. 2010; 10:53.
- 350 15. Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, and al. Role of occult
351 hepatitis B virus infection in chronic hepatitis C. *World J Gastroenterol.* 14 Nov.
352 2015;21(42):11931-40.
- 353 16. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult
354 hepatitis B virus infection in patients with chronic hepatitis C liver disease. *N Engl J Med.* 1
355 July. 1999;341(1):22-6.
- 356 17. Vivekanandan P, Daniel HD-J, Kannangai R, Martinez-Murillo F, Torbenson M. Hepatitis
357 B virus replication induces methylation of both host and viral DNA. *J Virol.* May
358 2010;84(9):4321-9.
- 359 18. Xu R, Zhang X, Zhang W, Fang Y, Zheng S, Yu X-F. Association of human APOBEC3
360 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and
361 hepatocellular carcinoma. *Hepatology Baltim Md.* Dec. 2007;46(6):1810-20.
- 362 19. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, and al. A genetic
363 variant of hepatitis B virus divergent from known human and ape genotypes isolated from a

- 364 Japanese patient and provisionally assigned to new genotype J. *J Virol.* Oct.
365 2009;83(20):10538-47.
- 366 20. Ma Y, Ding Y, Juan F, Dou XG. Genotyping the hepatitis B virus with a fragment of the
367 HBV DNA polymerase gene in Shenyang, China. *Virol J.* 22 June 2011;8:315.
- 368 21. Zhou J-Y, Zhang L, Li L, Gu G-Y, Zhou Y-H, Chen J-H. High hepatitis B virus load is
369 associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients:
370 a case control study. *Virol J.* 13 June 2012;9:16.
- 371 22. Ozaslan M, Ozaslan E, Barsgan A, Koruk M. Mutations in the S gene region of hepatitis B
372 virus genotype D in Turkish patients. *J Genet.* Dec. 2007;86(3):195-201.
- 373 23. Yeh C-T, Chen T, Hsu C-W, Chen Y-C, Lai M-W, Liang K-H, and al. Emergence of the
374 rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with
375 lamivudine-resistant chronic hepatitis B. *BMC Cancer.* 21 Sept. 2011;11:398.
- 376 24. Oluyinka OO, Tong HV, Bui Tien S, Fagbami AH, Adekanle O, Ojurongbe O, and al.
377 Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus
378 Transmission Risks. *PloS One.* 2015;10(7):e0131912.
- 379 25. Baghbanian M, Halvani M, Roghani HS, Lotfi MH, Yazdi MF. Prevalence of occult
380 hepatitis b infection in iranian cancer patients before chemotherapy treatment. *Arq*
381 *Gastroenterol.* Sept. 2016;53(3):175-9.
- 382 26. Banerjee A, Kurbanov F, Datta S, Chandra PK, Tanaka Y, Mizokami M, and al.
383 Phylogenetic relatedness and genetic diversity of hepatitis B virus isolates in Eastern India. *J*
384 *Med Virol.* Sept. 2006;78(9):1164-74.

- 385 27. Minuk GY, Sun D-F, Uhanova J, Zhang M, Caouette S, Nicolle LE, and al. Occult hepatitis
386 B virus infection in a North American community-based population. *J Hepatol.* April
387 2005;42(4):480-5.
- 388 28. Kurbanov F, Tanaka Y, Fujiwara K, Sugauchi F, Mbanya D, Zekeng L, and al. A new
389 subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A
390 and E in Cameroon. *J Gen Virol.* July 2005;86(Pt 7):2047-56.
- 391 29. Mulders MN, Venard V, Njayou M, Edoth AP, Bola Oyefolu AO, Kehinde MO, and al.
392 Low genetic diversity despite hyperendemicity of hepatitis B virus genotype E throughout West
393 Africa. *J Infect Dis.* 15 July 2004;190(2):400-8.
- 394 30. Makuwa M, Souquière S, Telfer P, Apetrei C, Vray M, Bedjabaga I, and al. Identification
395 of hepatitis B virus subgenotype A3 in rural Gabon. *J Med Virol.* Sept. 2006;78(9):1175-84.
- 396 31. Lin H, Zhao H, Tang X, Hu W, Jiang N, Zhu S, and al. Serological Patterns and Molecular
397 Characterization of Occult Hepatitis B Virus Infection among Blood Donors. *Hepat Mon.* Oct.
398 2016;16(10):e40492.
- 399 32. Hassan ZK, Hafez MM, Mansor TM, Zekri ARN. Occult HBV infection among Egyptian
400 hepatocellular carcinoma patients. *Virol J.* 3 March 2011;8:90.
- 401 33. Yousif M, Mudawi H, Hussein W, Mukhtar M, Nemer O, Glebe D, and al. Genotyping and
402 virological characteristics of hepatitis B virus in HIV-infected individuals in Sudan. *Int J Infect*
403 *Dis IJID Off Publ Int Soc Infect Dis.* Dec. 2014;29:125-32.
- 404 34. Torbenson M, Thomas DL. Occult hepatitis B. *Lancet Infect Dis.* August 2002;2(8):479-86.
- 405 35. Pernice W, Sodomann CP, Lüben G, Seiler FR, Sedlacek HH. Antigen-specific detection
406 of HBsAG-containing immune complexes in the course of hepatitis B virus infection. *Clin Exp*
407 *Immunol.* August 1979;37(2):376-80.

- 408 36. Brown SE, Howard CR, Steward MW, Ajdukiewicz AB, Whittle HC. Hepatitis B surface
409 antigen containing immune complexes occur in seronegative hepatocellular carcinoma patients.
410 Clin Exp Immunol. Feb. 1984;55(2):355-9.




Image 1: Photo of 2% agarose gel of genotypes E and A3.

medRxiv preprint doi: <https://doi.org/10.1101/2023.01.04.23284178>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .